121 related articles for article (PubMed ID: 7678359)
1. Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration.
Stormont TJ; Farrow GM; Myers RP; Blute ML; Zincke H; Wilson TM; Oesterling JE
Urology; 1993 Jan; 41(1):3-8. PubMed ID: 7678359
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.
Ghavamian R; Blute ML; Bergstralh EJ; Slezak J; Zincke H
Urology; 1999 Jul; 54(1):105-10. PubMed ID: 10414735
[TBL] [Abstract][Full Text] [Related]
3. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml.
Geary ES; Stamey TA
J Urol; 1996 Sep; 156(3):1056-8. PubMed ID: 8709306
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy.
Cookson MS; Fleshner NE; Soloway SM; Fair WR
Urology; 1997 Jun; 49(6):887-93. PubMed ID: 9187696
[TBL] [Abstract][Full Text] [Related]
5. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
Epstein JI; Walsh PC; Carmichael M; Brendler CB
JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.
Krumholtz JS; Carvalhal GF; Ramos CG; Smith DS; Thorson P; Yan Y; Humphrey PA; Roehl KA; Catalona WJ
Urology; 2002 Sep; 60(3):469-73; discussion 473-4. PubMed ID: 12350486
[TBL] [Abstract][Full Text] [Related]
7. PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors.
Oesterling JE; Suman VJ; Zincke H; Bostwick DG
Urol Clin North Am; 1993 Nov; 20(4):687-93. PubMed ID: 7505977
[TBL] [Abstract][Full Text] [Related]
8. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
Partin AW; Criley SR; Subong EN; Zincke H; Walsh PC; Oesterling JE
J Urol; 1996 Apr; 155(4):1336-9. PubMed ID: 8632568
[TBL] [Abstract][Full Text] [Related]
9. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.
Epstein JI; Chan DW; Sokoll LJ; Walsh PC; Cox JL; Rittenhouse H; Wolfert R; Carter HB
J Urol; 1998 Dec; 160(6 Pt 2):2407-11. PubMed ID: 9817393
[TBL] [Abstract][Full Text] [Related]
10. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations.
Ohori M; Wheeler TM; Scardino PT
Cancer; 1994 Jul; 74(1):104-14. PubMed ID: 7516262
[TBL] [Abstract][Full Text] [Related]
11. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
12. Preoperative predictors for organ-confined disease in Japanese patients with stage T1c prostate cancer.
Ogawa O; Egawa S; Arai Y; Tobisu K; Yoshida O; Kato T
Int J Urol; 1998 Sep; 5(5):454-8. PubMed ID: 9781434
[TBL] [Abstract][Full Text] [Related]
13. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Freedland SJ; Mangold LA; Epstein JI; Partin AW
Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological study of nonpalpable and nonvisible (stage T1c) prostate cancer].
Egawa S; Kuwao S; Soh S; Ohori M; Kawakami T; Uchida T; Yokoyama E; Koshiba K
Nihon Hinyokika Gakkai Zasshi; 1995 Jun; 86(6):1108-16. PubMed ID: 7541874
[TBL] [Abstract][Full Text] [Related]
15. Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer.
Ou YC; Chen JT; Yang CR; Cheng CL; Ho HC; Ko JL; Hsieh YS
Jpn J Clin Oncol; 2002 Dec; 32(12):536-42. PubMed ID: 12578903
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of prostate cancer found with early detection regimens.
Brendler CB
Urology; 1995 Sep; 46(3 Suppl A):71-6. PubMed ID: 7544517
[TBL] [Abstract][Full Text] [Related]
17. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
[TBL] [Abstract][Full Text] [Related]
18. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
19. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.
Partin AW; Mangold LA; Lamm DM; Walsh PC; Epstein JI; Pearson JD
Urology; 2001 Dec; 58(6):843-8. PubMed ID: 11744442
[TBL] [Abstract][Full Text] [Related]
20. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
